Log In
BCIQ
Print this Print this
 

tavilermide (MIM-D3)

  Manage Alerts
Collapse Summary General Information
Company Mimetogen Pharmaceuticals Inc.
DescriptionSmall molecule peptidomimetic of nerve growth factor (NGF)
Molecular Target Nerve growth factor (NGF)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationDry eye
Indication DetailsTreat dry eye syndrome; Treat keratoconjunctivitis sicca (KCS)
Regulatory Designation
PartnerAllergan plc

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

0

$50.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

11/04/2015

Undisclosed

$50.0M

Undisclosed

07/22/2013

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today